Congenital Lobar Emphysema
Links shared publicly online about this topic
Surgery Medical News about Congenital Segmental Emphysema
mdlinx.com — “Congenital Segmental Emphysema: An Evolving Lesion” View full resource at mdlinx.com
Most Recently Shared on May 3, 2010 at 6:25 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Congenital Segmental Emphysema: An Evolving Lesion: European Journal of Pediatric Surgery http://bit.ly/bsVaGm #SURG
Glassia approved for treating alpha 1 antitrypsin deficiency - MPR
empr.com — “Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).” View full resource at empr.com
Most Recently Shared on July 6, 2010 at 3:33 pm By:
MPR News: Glassia approved for treating alpha 1 antitrypsin deficiency: Kamada announced that the FDA has approved... http://bit.ly/bedZ9o
Glassia approved for treating alpha 1 antitrypsin deficiency - ONA
oncologynurseadvisor.com — “Kamada announced that the FDA has approved Glassia (alpha1-proteinase inhibitor liquid) for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor (AATD).” View full resource at oncologynurseadvisor.com
Most Recently Shared on July 6, 2010 at 3:53 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Glassia approved for treating alpha 1 antitrypsin deficiency http://goo.gl/fb/xUQkp
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency
news-medical.net — “Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled t” View full resource at news-medical.net
Most Recently Shared on February 6, 2010 at 4:52 am By:
FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficienc... http://bit.ly/9T7yWx
BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA
news-medical.net — “BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA" [Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as "genetic" or "congenital" emphysema.” View full resource at news-medical.net
Most Recently Shared on October 13, 2010 at 10:05 am By:
BioRx receives limited distribution rights from Baxter for AATD drug GLASSIA: BioRx, a specialty pharmacy company,... http://bit.ly/9n3jKH
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
Advertisement
